ISO27001 ≠ Annex 11: A Costly Misunderstanding in GMP Systems

We often hear the statement: “We’re ISO 27001 certified, so our GMP systems are covered”. It sounds reasonable at first. ISO27001 is about security, and GMP systems clearly rely on secure data and infrastructure. But in regulated life sciences, especially when patient safety and product quality are at stake, this assumption doesn’t hold up under regulatory scrutiny. Inspectors don’t see these two frameworks as interchangeable and confusing them can create real compliance gaps.

EU GMP Annex 11, Computerized Systems, is part of the EU GMP Guide (EudraLex Volume 4) and applies to all computerized systems used in GMP-regulated activities. Its purpose is very specific: to ensure that systems supporting manufacturing, testing, release and quality decisions are validated, reliable and fit for their intended use. Annex 11 places strong emphasis on data integrity, controlled system operation and lifecycle management, all with a clear link back to patient safety and product quality [1]. This is not theoretical guidance; it is a regulatory expectation that inspectors actively assess during GMP inspections.

ISO/IEC 27001 has a very different role. It is an international standard for establishing and maintaining an Information Security Management System. The standard is voluntary and applies across all industries, from finance and retail to healthcare and technology. Its objective is to help organizations protect information assets by managing risks to confidentiality, integrity and availability. While this is undoubtedly important in a pharmaceutical environment [2], ISO 27001 is fundamentally about organizational information security, not about proving that GMP systems consistently perform as required for regulated use.

This difference in purpose is matched by a difference in legal status. Annex 11 is a GMP regulatory requirement. Compliance is expected and enforced by the EMA, national competent authorities, and PIC/S inspectors. Failure to meet Annex 11 expectations can result in inspection findings or worse. ISO 27001, by contrast, is not a regulation. Certification demonstrates adherence to a recognized best-practice standard, but it does not carry regulatory authority. During an inspection, an ISO certificate may be noted, however it will not replace the need for GMP-specific evidence [1, 2, 3, 4]. In pharmaceutical manufacturing, regulatory compliance always outweighs certification status.

Another key distinction lies in validation versus management systems. Annex 11 is centered on validation and lifecycle control of computerized systems. Regulators expect documented evidence that a system has been validated for its intended use, that it performs consistently, and that risks have been assessed with a focus on patient safety and data integrity. Changes to systems must be controlled, assessed, and justified within a GMP framework [1,5]. ISO 27001 does not require this level of system-specific validation. It focuses instead on establishing a structured approach to identifying, evaluating, and treating information security risks at an organizational level, supported by policies, governance, and continuous improvement [2]. A company can be fully ISO27001 certified without ever producing validation protocols, test scripts, or traceability matrices that inspectors expect to see.

Data integrity is another area where the differences become very clear. In the GMP world, Annex 11 aligns with data integrity expectations such as ALCOA+. Inspectors look for the ability to reconstruct events, understand who did what and when, and trust the data used to make quality decisions [1,3]. ISO27001 approaches integrity through the CIA triad, where integrity refers to protecting information from unauthorized modification [2]. While related, this is not the same. Securing data is important, but security alone does not prove compliance, traceability, or trustworthiness of GMP records.

These differences become especially visible in day-to-day compliance topics such as audit trails, change control, and supplier management. Annex 11 expects complete and reviewable audit trails for GxP data, validated and documented changes, and clearly defined supplier responsibilities within a risk-based GMP context [1]. ISO 27001 can support aspects like security logging, general change management processes, and supplier risk treatment, but it does not inherently ensure that audit trails meet GMP expectations or that changes are validated and documented in a way that satisfies inspectors [2]. The evidence required for a GMP inspection goes far beyond what an ISMS typically produces.

The bottom line is simple. Even if an organization has a mature information security program and holds an ISO 27001 certificate, that certification does not replace the need for Annex 11 compliant validation documentation [3]. ISO 27001 can support and strengthen a GMP environment, but it cannot stand in for regulatory requirements. Inspectors do not ask for ISO certificates, they ask for evidence of compliance to Annex 11.

The real regulatory takeaway is not that one framework is better than the other, but that they serve different purposes. ISO 27001 is valuable for building a structured, risk-aware approach to information security. Annex 11 is essential for demonstrating that computerized systems do what they are supposed to do in a GMP context, every time, in a way that protects patients and product quality. In regulated life sciences, you don’t replace one with the other, you integrate them properly.

Unsure whether your ISO 27001 program truly supports your GMP compliance obligations? Many organizations discover too late that security certification alone does not satisfy Annex 11 expectations. Our consulting firm specializes in GMP data integrity and computer system validation, helping life sciences companies translate regulatory requirements into practical, inspection-ready solutions. If you want confidence that your computerized systems meet Annex 11 requirements (not just security best practices) contact us to discuss how we can support your compliance journey!

References:
[1] European Commission, EudraLex – Volume 4 – EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 11: Computerised Systems.
[2] International Organization for Standardization (ISO) and International Electrotechnical Commission (IEC). ISO/IEC 27001:2022 — Information security management systems — Requirements.
[3] Pharmaceutical Inspection Co-operation Scheme (PIC/S). Guide to Good Manufacturing Practice for Medicinal Products, PI 009, including Annex 11: Computerised Systems.
[4] European Commission. Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use.
[5] European Commission. Concept Paper on the Revision of Annex 11 of the EU Guidelines for Good Manufacturing Practice for Medicinal Products – Computerised Systems. EudraLex, Volume 4.